UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe

Social Psychiatry and Psychiatric Epidemiology, 2021-03, Vol.56 (3), p.409-416

2021

Volltextzugriff (PDF)

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis

Clinical pharmacology in drug development, 2023-01, Vol.12 (1), p.94-106

2023

Volltextzugriff (PDF)

A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State

Clinical pharmacology in drug development, 2024-03, Vol.13 (3), p.224-232

2024

Volltextzugriff (PDF)

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

Journal of Alzheimer's disease, 2017-01, Vol.55 (1), p.19

2017

Volltextzugriff (PDF)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

Clinical pharmacology in drug development, 2021-06, Vol.10 (6), p.647-659

2021

Volltextzugriff (PDF)

Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease

Journal of Huntington's disease, 2020-01, Vol.9 (2), p.173

2020

Volltextzugriff (PDF)

Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease

Journal of Parkinson's disease, 2015-01, Vol.5 (3), p.581

2015

Volltextzugriff (PDF)

The Patient-Reported Outcome (PRO) Consortium: Lessons Learned Along the Path to PRO Instrument Qualification

Therapeutic innovation & regulatory science, 2015-01, Vol.49 (1), p.132-138

2015

Volltextzugriff (PDF)

Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

The American journal of geriatric psychiatry, 2022-03, Vol.30 (3), p.360-371

2022

Volltextzugriff (PDF)

On crushing of deutetrabenazine tablets

American journal of health-system pharmacy, 2021-09, Vol.78 (17), p.1551-1552

2021

Volltextzugriff (PDF)

Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge

Alzheimer's & dementia, 2016-09, Vol.12 (9), p.1014-1021

2016

Volltextzugriff (PDF)

Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation

Alzheimer's & dementia, 2016-09, Vol.12 (9), p.1022-1030

2016

Volltextzugriff (PDF)

Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic Review

Journal of Alzheimer's disease, 2015-01, Vol.48 (2), p.355

2015

Volltextzugriff (PDF)

Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Lancet neurology, 2024-03, Vol.23 (3), p.243-255

2024

Volltextzugriff (PDF)

F1‐02‐03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF‐AD BIOMARKER DISCOVERY STUDY

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_3), p.P202-P204

2018

Volltextzugriff (PDF)

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

Nature reviews. Drug discovery, 2017-10, Vol.16 (10), p.736-736

2017

Volltextzugriff (PDF)

P1‐324: Predicting Change in Hippocampal Volume Using MRI Features from Baseline

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_11), p.P550-P551

2016

Volltextzugriff (PDF)

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

Movement disorders, 2008-07, Vol.23 (10), p.1353-1360

2008

Volltextzugriff (PDF)

UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1312-P1313

2017

Volltextzugriff (PDF)

P2‐134: Clinical characteristics of subjects with conflicting biomarkers of amyloid deposition

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_11), p.P535-P536

2015

Volltextzugriff (PDF)

Predictors of placebo response in restless legs syndrome studies

Neurology, 2013-07, Vol.81 (2), p.193

2013

Volltextzugriff (PDF)

PREDICTING CHANGE IN HIPPOCAMPAL VOLUME USING MRI FEATURES FROM BASELINE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P550-P551

2016

Volltextzugriff (PDF)

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

Movement disorders, 2009-03, Vol.24 (4), p.564-573

2009

Volltextzugriff (PDF)

P2‐345: WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST‐OLD? THE EMIF‐AD 90+ STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_14), p.P726-P727

2019

Volltextzugriff (PDF)

WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST-OLD? THE EMIF-AD 90+ STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P726-P727

2019

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

ThemaMovement Disorders

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(76)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis

A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease

Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease

The Patient-Reported Outcome (PRO) Consortium: Lessons Learned Along the Path to PRO Instrument Qualification

Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

On crushing of deutetrabenazine tablets

Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge

Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation

Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic Review

Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

F1‐02‐03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF‐AD BIOMARKER DISCOVERY STUDY

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

P1‐324: Predicting Change in Hippocampal Volume Using MRI Features from Baseline

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE

P2‐134: Clinical characteristics of subjects with conflicting biomarkers of amyloid deposition

Predictors of placebo response in restless legs syndrome studies

PREDICTING CHANGE IN HIPPOCAMPAL VOLUME USING MRI FEATURES FROM BASELINE

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

P2‐345: WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST‐OLD? THE EMIF‐AD 90+ STUDY

WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST-OLD? THE EMIF-AD 90+ STUDY

Aktive Filter

Suchergebnisse filtern